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recommended. Serum valproate levels range from 50 μg/
mL to 125 μg/mL, although a level more than 100 μg/mL 
in acute ingestion may be considered to be toxic and in 
levels higher than this cutoff point, hemodialysis may 
contribute to VPA elimination.[2,5,6]
When serum VPA level is over 100-150 μg/mL, protein 
sites are saturated leading to increased levels of the 
free drug.[2,3,5] VPA enhances gamma-aminobutyric 
acid synthesis and release in some specific areas 
of the brain that can control seizure onset and 
propagation.[2,6] Furthermore, VPA reduces the release 
INTRODUCTION
Valproic acid (VPA) or valproate is an effective 
antiepileptic drug widely used all over the world 
and approved for the treatment of both partial 
and generalized seizures.[1-4] It is also used to treat 
bipolar and schizoaffective disorders, social phobias, 
neuropathic pain, and for prophylaxis or treatment of 
migraine headaches.[2,3] The usual daily dose of 1-2 g 
in adults and 15-60 mg/kg in children is generally 
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of the epileptogenic acid and changes dopaminergic and 
serotoninergic neurotransmissions.[2,7] As VPA use has 
increased, reports on both accidental and intentional 
intoxications are increasing.[2,3,6]
VPA overdose usually causes mild and self-limited central 
nervous system depression. However, serious adverse 
effects and even death have been reported.[8,9] In addition to 
central nervous system depression, VPA toxicity may cause 
cerebral edema, hyperammonemia, and hepatotoxicity.[7,10]
Recent articles have shown that hepatotoxicity induced 
by VPA can be managed by L-carnitine. L-carnitine also 
increases the survival rate of these patients, especially in 
cases referred with coma, rising ammonia level, or VPA 
levels greater than 450 μg/mL.[3,11,12] However, some experts 
believe that L-carnitine has no specific therapeutic effect 
in acute overdose.[13] Despite several studies indicating 
the usefulness of intravenous L-carnitine in the treatment 
of VPA poisoning, this drug is not readily available in 
Iran. Many patients with severe acute VPA toxicity are 
supportively treated. The objective of this study was, 
therefore, to determine whether supportive care without 
antidote would result in acceptable outcome in acutely VPA 
poisoned patients and to find out the factors associated with 
poorer outcomes.
MATERIALS AND METHODS
After approval of the Ethical Committee of Human Research 
of the Clinical Research Development Center, all patients 
>12-year-old with acute VPA overdose who had been 
referred to Loghman-Hakim Hospital between 2009 and 
2013 were consecutively enrolled. Those with multidrug 
ingestions were excluded [Figure 1]. In this observational, 
retrospective, single-center case series, patients were 
identified using the International Classification of Disease 
Codes (ICD10 codes version 2010). Those with code T42-6 
(poisoning chapter; poisoning by antiepileptics, sedative-
hypnotics, and antiparkinsonism drugs), X41 (accidental 
poisoning by and exposure to antiepileptics), X61 (intentional 
self-poisoning by and exposure to antiepileptics), and 
Y11 (antiepileptic poisoning, undetermined intent) were 
evaluated.
Patients’ demographic and presenting features, physical 
examinations, laboratory data, treatment modalities, 
and outcomes were recorded. On arrival, vital signs and 
laboratory findings, as well as those after initial stabilization 
(averagely 6 h after admission), were checked. The time 
elapsed between ingestion and presentation, as well as the 
ingested amount, was also recorded based on the patients’ 
report or hospital admission. Severe toxicity was defined 
as the need for intubation and/or hemodialysis or death 
during hospitalization and those with poor prognosis were 
considered to have severe toxicity in the current study. 
Severity of poisoning was also determined based on the 
ingested dose as follow: Severe toxicity (>28 g or ~400 mg/
kg), probable moderate toxicity (>14 g or ~200 mg/kg), 
probable mild toxicity (>1.8 g), and probable nontoxic 
ingestion (<1.8 g).[13,14] Patients with severe toxicity were 
compared to the remainder in order to determine the 
independent variables which would cause a worse outcome. 
The normal range of aspartate transaminase (AST), alanine 
transaminase (ALT), alkaline phosphatase (ALK/P), and 
carnitine phosphokinase were considered to be 5-40 IU/L, 
7-56 IU/L, 44-147 IU/L, and 140-280 IU/L, respectively.[15]
All the patients had received standard care, including 
airway management, intravenous fluid resuscitation, 
gastrointestinal lavage, activated charcoal and sorbitol, and 
Intensive Care Unit (ICU) care/hemodialysis if indicated. 
As we did not access the serum level of VPA in all cases 
(just in 19.6%) and L-carnitine was also unavailable, we 
treated the patients conservatively and dialyzed them when 
they did not respond to conservative treatment. Activated 
charcoal was given within the 1st h postingestion, if the time 
of overdose was known. Intravenous L-carnitine was not 
prescribed to any patient because it is not available in Iran. 
This study was approved by the institutional review board.
Statistical analysis was performed by Statistical Package for 
Social Sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL, 
USA) using Shapiro-Wilk, Chi-square and Fisher’s exact 
tests, Wilcoxon signed-rank test, Mann-Whitney U-test, 
Kruskal-Wallis H-test, and binomial logistic regression test. 
Statistical significance was set at P < 0.05.
RESULTS
Of a total of 715 patients, 316 were enrolled as pure VPA 
toxicity [Figure 1] with a female to male ratio of 2.55. The Figure 1: Selection and outcome of participants recruited in the study
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median (interquartile range [IQR]) age was 23 (18, 30 [range; 
10-66 years]). The median (IQR) ingested dose of VPA was 
600 (400, 1000 mg [range; 400-4000 mg]). However, the exact 
intake dose of 44 patients (13.9%) was unknown. In 286 
patients (90.5%), the exact time of ingestion was reported 
by the patients themselves or their accompanying relatives. 
Median (IQR) time elapsed between drug ingestion and 
hospital presentation was 4 (2, 7 h [range; 1-72 h]). All the 
patients had deliberately poisoned themselves as confirmed 
by psychiatric assessments. Gastric lavage and/or activated 
charcoal administration were performed in 178 (56.3%) 
patients. The most common underlying diseases were 
epilepsy (56 patients), psychosis (32 patients), depression 
(24 patients), and migraine headaches (13 patients). 
However, 166 (52.5%) intoxicated cases did not have any 
underlying diseases. The most common presenting signs/
symptoms were drowsiness (70 patients, 22.2%), nausea and 
vomiting (60 patients, 19.1%), vertigo (43 patients, 13.6%), 
and headache (34 patients, 10.8%).
In 223 cases (70.6%), electrocardiograms (ECGs) were normal 
on presentation. The most common ECG abnormalities 
included sinus tachycardia (46 patients, 14.6%) followed by 
sinus bradycardia (16 patients, 5.1%). In the course of the 
disease, 14 patients (4.4%) were intubated and three (0.9%) 
required hemodialysis with the mean dialysis sessions of two. 
ICU admission was needed in 14 patients (4.4%). Mean ICU 
stay was 80 ± 57 h while the median (IQR) hospital stay was 
15 (12, 24) h. Seizures occurred in five patients (1.4 %) during 
hospitalization, none of whom had a history of epilepsy. The 
average ingested dose of VPA was 6.5 ± 6.3 g (range, 2-16 g). 
There was no association between the occurrence of seizures 
and poor outcomes (P = 0.204, Fisher’s exact test).
The initial level of consciousness was lower in patients 
with poor outcomes. On the other hand, only 0.7% of 
the patients who discharged without any complications 
had been admitted to an emergency department in coma. 
Table 1 shows the comparison between the patients with 
fair and poor outcomes. A total of 7.6% and 1.4% of the 
patients had abnormal AST and ALT on admission with 
no significant association between these tests and patients’ 
outcome. ALK/P was abnormal in 56% of the patients who 
had the documented levels of this test in their files and was 
not significantly different between those with fair and poor 
outcomes. None of the patients with nontoxic ingestions 
(<1.8 g) had abnormal AST, ALT, or ALK/P. Table 2 
shows that although there was a significant correlation 
between probable mild/moderate/severe toxicity based 
on the ingested dose and poor outcome (P < 0.005), such a 
significant relation was not found between VPA level and 
outcome (P = 0.404, Kruskal-Wallis test). Table 3 shows the 
characteristics of 14 patients with poor outcomes.
The median ingested dose of VPA in patients who required 
dialysis was significantly higher (20 vs. 6 g; P = 0.006). 
However, median VPA serum concentration failed to show 
such significant difference between the two groups (150 vs. 
Table 1: Comparison between the patients with good and poor outcome
Variable Total  
(n = 316)
Good outcome 
(n = 302)
Poor outcome 
(n = 14)
P value (applied 
statistical test)
Age 23 (18, 30) 22.5 (18, 29) 31.5 (26, 47.5) 0.003 (MWU)
Gender
Female 227 (71.8) 219 (72.5) 8 (57.1) NS (Pearson χ2)
Male 89 (28.2) 83 (27.5) 6 (42.9)
Ingested dose (g) 6 (4, 10) 6 (4, 10) 17 (6, 20) 0.002 (MWU)
Time elapsed (h) 4 (2, 7) 4 (2, 7) 5 (3, 6.5) NS (MWU)
Serum concentration (μg/mL) 118 (37, 188) 117 (31, 186) 129 (47, 226) NS (MWU)
Coma on presentation
Yes 9 (2.8) 2 (0.7) 7 (77.8) 0.0005 (Fisher 
exact test)No 297 (97.2) 300 (99.3) 2 (22.2)
SBP (mmHg) 110 (110, 120) 110 (110, 120) 120 (100, 122) NS (MWU)
DBP (mmHg) 70 (65, 80) 70 (65, 80) 70 (60, 80) NS (MWU)
RR (per min) 16 (14, 18) 16 (14, 18) 16 (13, 18) NS (MWU)
HR (per min) 82 (80, 90) 82 (80, 90) 84 (78, 100) NS (MWU)
Axillary T (°C) 37 (37, 37) 37 (37, 37) 37 (37, 37) NS (MWU)
pH 7.39 (7.35, 7.42) 7.39 (7.35, 7.41) 7.42 (7.34, 7.45) NS (MWU)
PCO2 (mEq/L) 41.1 (36.2, 45.9) 41.2 (36.7, 46.7) 34.6 (29.5, 44.5) 0.045 (MWU)
HCO3 (mEq/L) 24.2 (21.7, 27.3) 24.9 (22.1, 27.3) 21 (19.4, 24.1) 0.01 (MWU)
BE (mEq/L) 0 (−3, 1.9) 0.3 (−2.8, 2.3) −2.5 (−4.3, −1.2) 0.03 (MWU)
CPK (IU/L) 99 (65, 155) 100 (72, 196) 60 (44, 127) 0.038 (MWU)
Hospital stay (h) 15 (12, 24) 15 (11, 24) 104 (52, 127) 0.0005(MWU)
Data were presented as median value (inter quartile range) or n (%). MWU = Mann-Whitney U-test; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; RR = Respiration 
rate; HR = Heart rate; CPK = Creatine phosphokinase; NS = Not significant
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117 μg/mL; P = 0.182). Ammonia level was not measured in 
any of the patients who underwent dialysis.
Evaluation of the platelets using Wilcoxon signed-rank 
test showed no evidence to approve thrombocytopenia 
as an indicator of severe valproate toxicity. On the other 
hand, pH, PCO2, HCO3, and liver function tests (AST, ALT, 
and ALK/P) evaluated in the patients with poor outcomes 
showed no statistically significant difference between these 
parameters on admission and before death or discharge 
(Wilcoxon signed-rank test). Multivariate analysis revealed 
that coma on presentation was associated with the worst 
outcome (P = 0.001; odds ratio = 61.5; 95% CI = 5.8-646.7).
DISCUSSION
There is no controlled, randomized trial that delineate the 
therapeutic and prophylactic roles of L-carnitine and the 
optimal regimen of its administration in VPA toxicity. To 
compare treatment with or without L-carnitine, the only 
way is to review those studies that used this antidote and 
compare final outcomes with the ones which did not use it.
Valproate is widely prescribed for the treatment of epilepsy 
with few side effects although its toxicity has been steadily 
increasing in frequency worldwide.[1,3,6,16-19] Our previous 
data from 2003 showed that in 6 months only 51 pure VPA 
toxicity cases had been admitted to our center.[20] In the 
current study, 316 cases were hospitalized in 36 months 
which again confirms this claim. The frequency of 
anticonvulsant and benzodiazepine toxicities were almost 
constant between 2006 and 2011 (F [5-2.70] = 0.22, P = 0.93).[21]
VPA is generally well tolerated, but rare serious adverse 
events may occur in some patients receiving it, including 
hemorrhagic pancreatitis, bone marrow suppression, 
hepatotoxicity, and VPA-induced encephalopathy.[2] Our 
data showed no sign of bone marrow suppression including 
thrombocytopenia in our patients during hospitalization. 
The same results were found by Isbister et al.[16] On the other 
hand, while liver function tests did not significantly affect 
the patients’ outcome, ALK/P was interestingly high in the 
majority of the patients with ingestion of toxic doses (56%).
Initial vital signs were shown to have no significant effect 
on the final outcome of the patients. In univariate analysis, 
the only independent factors which correlated with poorer 
outcome were older age, higher ingested doses, coma on 
presentation, lower PCO2, HCO3, base excess, and CPK, and 
not surprisingly, prolonged hospital stay [Table 1]. Unlike 
Spiller et al. and Thanacoody studies, we could not find any 
association between serum VPA level and outcome.[8,22] This 
may be due to different presentation and sampling times.
Although it is claimed that the massive overdoses (>400 
mg/kg) of valproate are potentially life-threatening and can 
lead to poor outcomes, we had some patients presenting 
with mild overdoses who developed hepatotoxicity, loss 
of consciousness, and even death. Overall, the outcome 
is good in VPA toxicity and the number of patients with 
Table 3: On-arrival characteristics of 14 intubated patients
n Age (years) 
and gender
Elapsed hours 
(ingestion-
admission)
Dose 
(g)
Serum 
concentration 
(μg/mL)
Coma on 
presentation
Acidosis ECG 
findings
Abnormal 
LFT
Dialysis/
numbers
Hospital 
stay (h)
Death
1 37 female — 20 120 No No Normal Yes Yes/3 264 No
2 29 female 5 — — Yes No Tachycardia No No 120 No
3 35 male — 30 550 Yes Yes Normal Yes Yes/1 80 Yes
4 20 female — 20 54 Yes No Normal No No 120 No
5 50 male 7 60 129 No No Tachycardia Yes No 110 Yes
6 33 male 3 — — No No Normal Yes No 30 No
7 28 female 1 16 150 No No Normal Yes Yes/2 210 No
8 53 female 4 4 — No No Prolonged QT No No 40 No
9 20 female — 6 — Yes No Tachycardia Yes No 60 No
10 16 female 3 20 303 Yes Yes Normal Yes No 56 No
11 28 male 19 18 22.5 Yes Yes Normal Yes No 148 No
12 49 male — — 41.8 Yes No Normal Yes No 20 No
13 47 female 6 10 229 No No Tachycardia No No 98 No
14 3 male 5 20 120 No No Normal No No 120 No
Acidosis and LFT were evaluated during hospitalization. LFT = Liver function tests; ECG = Electrocardiogram
Table 2: Correlation of ingested dose and poor outcome 
in 272 patients with known ingested dose
Characteristics Potentiality of toxicity
Nontoxic Mild Moderate Severe Total
Good outcome 
number (%)
15 (100) 224 (98.2) 21 (80.8) 2 (66.7) 262 (96.3)
Poor outcome 
number (%)
0 4 (1.8) 5 (19.2) 1 (33.3) 10 (3.7)
Total 
number (%)
15 (100) 228 (100) 26 (100) 3 (100) 272 (100)
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poor outcome is quite few (4.4%) and death is uncommon 
(0.6%). Most studies on VPA toxicity are case reports. Isbister 
et al. reported a fatal case of VPA toxicity among 79 cases; 
however, it was a mixed ingestion of drugs.[16] We had no 
deaths in our previous study in 51 pure VPA toxicity cases.[20]
Published evidence on the efficacy and safety of L-carnitine 
for acute VPA overdose is not enough.[1,2] Perrott et al. 
stated that it was reasonable to consider L-carnitine for 
patients with acute VPA overdose and decreased level of 
consciousness.[23] Mock and Schwetschenau concluded that 
oral levocarnitine was safe and effective in VPA-induced 
encephalopathy.[24] L-carnitine has also been used with 
questionable benefit in the setting of acute VPA-induced 
hepatitis.[25] In a recent study, Lheureux and Hantson 
mentioned that early intravenous L-carnitine improved 
survival in severe VPA-induced hepatotoxicity.[1] In 
our study, intravenous L-carnitine was not used and 
conservative management had arguably resulted in the 
similar results. We are not yet able to decline or confirm the 
usefulness of L-carnitine in acute VPA toxicity although it 
seems a safe antidote.[11,13,18,23,24]
In terms of hemodialysis, we were not dependent on 
ammonia level.[22] Hemodialysis was done in three patients 
unresponsive to supportive care and the progress of the 
loss of consciousness and probable encephalopathy. None 
of them had a serum VPA more than 850 μg/mL which was 
considered for HD by previous studies.[16,22] One of the dead 
cases was dialyzed one time and we think that early HD 
might have saved his life. L-carnitine may be used in this 
situation as well, but the formation of ammonia is higher 
due to higher VPA concentrations. Some authors suggest 
measuring ammonia during VPA toxicity treatment.[25]
STRENGTH AND LIMITATIONS
To the best of our knowledge, this is the largest single-center 
study on pure VPA toxicity. The retrospective nature of this 
study along with missing data, lab tests, valproate level 
(measured in 62 cases), and ammonia level (measured in 
only three cases) were definitely the main limitations of this 
study. The valproate level was not measured on arrival in 
all the cases; thus there was no correlation between ingested 
dose and valproate level. Inability to follow all outpatients 
in order to measure the probable late consequences of VPA 
toxicity is another potential limitation.
CONCLUSIONS
The prognosis of patients with acute VPA toxicity appears 
to be good even with supportive care. According to our 
study, the main poor prognostic factor is coma in the 
multivariate analysis which may be seen after the ingestion 
of doses as low as 6 g. In univariate analysis, older age and 
ingestion of higher amounts of VPA prone the patients to 
more severe toxicities. Lower PCO2, HCO3, BE, and CPK are 
other variables which can be used to predict the outcome 
of toxicity.
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